Qiming Venture Partners

Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Ryan Baker

CFO

Cyrus Chan

Associate

Nan Chen

Principal

David Chu

Partner

Isaac Ciechanover

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Vice President

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho

Venture Partner

William Hu

Managing Partner

Duane Kuang

Co-Founder and Managing Partner

Nisa Leung

Managing Partner

Dingzheng Li

Vice President

Jing Liu

Vice President

Chang Liu

Associate

Bin Liu

Vice President

Biao Lu

Associate

Shuo Mao

Principal

Will McConnell

Principal

Gary Rieschel

Managing Partner

James Shen

Venture Partner

Motao Sun

Vice President

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Rachel Wang

Venture Partner

James Wang

Venture Partner

Xu Gillian

RMB funds CFO

Peter (Ming) Yin

Principal, Cleantech

Janet Yu

Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Managing Partner

Zhiyuan Zhou

Associate

Zhifeng Zhou

Managing Partner

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

Past deals in Healthcare

Eco Polymer

Series B in 2025
Eco Polymer specializes in research and the production of medical catheters and membrane materials.

Singular Medical

Series C in 2025
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

Weimei Health

Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology

TOPI Imaging Technology

Series E in 2025
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.

Pulnovo Medical

Series C in 2025
Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Nanos Medical

Venture Round in 2025
Nanos Medical specializes in the research, development, manufacturing, and sales of disposable medical devices, primarily targeting the cardiovascular and ear, nose, and throat (ENT) fields. The company offers a range of innovative products, including sinus balloon catheters, eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal balloons, and drug-eluting stents for sinus applications. Through its advanced medical devices, Nanos Medical aims to enhance treatment options for hospitals and patients, contributing to improved healthcare outcomes.

Vivatides Therapeutics

Series C in 2025
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.

Stairway Medical

Series B in 2025
Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Xinzeyuan

Series B in 2025
Xinzeyuan Medical specializes in the manufacturing of critical precision components and disposable medical endoscopes, serving primarily hospital clients. Their product portfolio includes minimally invasive surgical instruments and other medical consumables, aiming to enhance safety and efficiency in surgical procedures for healthcare professionals.

Iongen Therepeutics

Seed Round in 2025
Iongen Therepeutics is an innovative drug research and development company focusing on pain treatment.

Umoja Biopharma

Series C in 2025
Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Cornerstone Robotics

Series C in 2025
Cornerstone Robotics is a company dedicated to enhancing the accessibility of advanced medical services in China through the development of innovative medical robotic devices. Its primary focus lies in creating a safe and efficient surgical robotics platform that empowers physicians to perform surgeries with greater accuracy and efficiency. By investing in research and development, Cornerstone Robotics aims to advance the field of surgical robotics, thereby improving patient outcomes and transforming surgical practices.

Soda Health

Series B in 2024
Soda Health, established in 2021 with its headquarters in Chicago, Illinois, is a healthcare technology company focused on reducing health disparities by addressing social determinants of health. The company operates a platform designed to help individuals identify, access, and afford necessary resources for leading healthier lives. This platform facilitates personalized benefit administration and reimbursement, bridging the gap between medical claims and retail payments more cost-effectively than traditional methods.

Bioheng

Series C in 2024
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Dearer Medical

Venture Round in 2024
Dearer Medical is a medical device company based in China that specializes in the development, production, and sales of eye-related products, particularly contact lenses. The company is dedicated to research and development in this field, focusing on both practical and fashionable color contact lens options. By combining innovation with quality manufacturing, Dearer Medical aims to meet the diverse needs of customers seeking enhanced vision solutions.

Tianhu Technology

Series A in 2024
Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

XellSmart

Series B in 2024
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Tachem

Series B in 2024
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, among others. Tachem's primary offerings comprise protective amino acids, non-natural amino acids, and high-quality chemical raw materials, serving as biotechnical solutions for various industrial users.

Hope Medicine

Series B in 2024
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.

Longbio Pharma

Series B in 2024
LongBio Pharma is a biotechnology company focused on developing treatments for patients with complement and allergy-related diseases within the autoimmune field. The company aims to improve patient outcomes by providing affordable and high-quality biomedicines. Through its innovative platform, LongBio Pharma works to bring its therapeutic solutions to both domestic and international markets, enabling healthcare professionals to offer enhanced treatment options to their patients.

Candid Therapeutics

Series A in 2024
Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Epigenic Therapeutics

Series A in 2024
Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Zhongyi Rehabilitation

Seed Round in 2024
Zhongyi Rehabilitation is a provider of rehabilitation products and services that focuses on the operation of chain rehabilitation centers to provide patients with one-stop professional rehabilitation needs and solutions.

SinoUnited Health

Series D in 2024
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopedics, and neurology services. Established in 2004, the center offers a wide range of treatments, including services for foot and ankle issues, acupuncture, chronic pain, movement disorders, migraines, tremors, electromyography, balance training, home exercise programs, manual therapy, post-stroke care, post-herpetic neuralgia, osteoarthritis, and carpal tunnel syndrome. Known for its commitment to high-quality patient care, SinoUnited Health integrates thoughtful design with international standards to enhance the patient experience. The center has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, ensuring high levels of customer satisfaction among both local residents and visitors.

Chenzhang Biotechnology

Seed Round in 2024
Chenzhang Bio is a biotechnology developer specializing in stem cell storage and treatment technology. focusing on stem cell storage and treatment technologies, company's research and commercialization, enhancing its R&D team and promoting clinical application of stem cell treatment technology

Dr.Clear Aligner

Series A in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.

CSR Biotech

Series A in 2024
CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.

LTZ Therapeutics

Series A in 2024
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

SonoSilicon

Angel Round in 2024
SonoSilicon researches on medical-grade micro-on-chip ultrasound systems and chip design and promotes the medical device industry.

DK Medtech

Series E in 2024
DK Medtech is a medical technology company based in Suzhou, China, specializing in the development and production of balloon catheter medical devices. Founded in 2015, the company has positioned itself as a leader in the medical device industry, focusing on innovative solutions to address complex healthcare challenges. Through its commitment to excellence, DK Medtech aims to improve patient outcomes and enhance the quality of healthcare.

Simaixu Biotechnology

Angel Round in 2024
Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies

Novamab

Series B in 2024
Novamab is a biotechnology company specializing in the development of novel nanobodies, a type of single-domain antibody with unique therapeutic advantages. With over 15 years of experience in nanobody research and development, the company's team of pioneers in this field has established platforms to maximize the potential of nanobodies. Novamab focuses on creating innovative drug formulations such as inhaled macromolecular drugs, albumin nanobody long-acting therapies, and nanobody double-antibody combinations. Their primary goal is to address unmet clinical needs by improving administration methods and reducing treatment cycles for major chronic diseases like cancer, autoimmune disorders, and cardiovascular conditions.

Thorough Future

Series A in 2024
Thorough Future specializes in incorporating advanced technology into medical care, focusing on improving diagnostic services in clinical medicine. The company develops artificial intelligence solutions to enhance pathology image diagnosis, utilizing big data and AI to deliver intelligent diagnostic and predictive services. By doing so, Thorough Future aims to increase the efficiency of diagnoses and offer personalized treatment recommendations, particularly for cancer patients, thus contributing to improved patient outcomes in healthcare.

Dezhen Technology

Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.

Yanshengchao

Angel Round in 2024
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

Brise Pharma

Seed Round in 2024
Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

GenEditBio

Seed Round in 2024
GenEditBio is a biotechnology company dedicated to developing innovative gene editing therapies aimed at addressing unmet medical needs in the treatment of genetic diseases. The company focuses on the research and development of advanced in vivo gene editing tools and effective delivery systems. Through its efforts, GenEditBio seeks to provide curative solutions that leverage gene editing technology to improve patient outcomes and address the challenges posed by various genetic disorders.

Emulate

Series F in 2024
Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

Chunyu Yisheng

Venture Round in 2024
Chunyu Yisheng, established in 2011 and headquartered in Beijing, is a mobile application designed to enhance communication between physicians and patients. The app allows doctors to access their patients' medical records and facilitates direct interaction, enabling patients to schedule appointments and communicate with their healthcare providers. Additionally, Chunyu Yisheng offers reservation line treatment services, further supporting users in managing their health. The company focuses on leveraging Internet technology to improve health outcomes and streamline the healthcare experience.

Pinnacle Medicines

Series A in 2024
Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide modalities to address various medical needs. Utilizing AI-based drug design tools, Pinnacle Medicines conducts research aimed at creating safe, effective, and convenient therapeutics for unmet medical conditions. Through its innovative approach, the company seeks to enhance the efficacy of peptide drugs in the pharmaceutical landscape.

Dr.Clear Aligner

Series F in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.

Hope Medicine

Series B in 2024
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.

Jasper Therapeutics

Post in 2024
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Yibai Health

Venture Round in 2023
Yibai Health is a clinical research medical group that builds clinical trial centers for hospitals.

Prime Lifescience

Seed Round in 2023
Prime Lifescience is a developer of a big data platform tailored for the life sciences sector. The company focuses on creating a health lifecycle big data collaboration network through digital technology innovation and the extensive application of artificial intelligence. Prime Lifescience offers a digital smart health community, an intelligent clinical research accelerator, and a live big data platform. These offerings aim to enhance digital clinical research and foster a comprehensive medical solutions environment, ultimately benefiting the healthcare sector through improved data-driven insights and collaboration.

Tachem

Series A in 2023
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, among others. Tachem's primary offerings comprise protective amino acids, non-natural amino acids, and high-quality chemical raw materials, serving as biotechnical solutions for various industrial users.

Wecare Probiotics

Series D in 2023
Wecare Probiotics is a national high-tech enterprise focused on the research and development, production, and application of probiotic strains. The company offers a diverse range of probiotic products, including fermented food strains and beneficial microbial flora, suitable for various industries such as food, healthcare, and medicine. By prioritizing quality and efficiency, Wecare Probiotics aims to deliver effective solutions that meet the needs of its customers.

Congnitact

Series A in 2023
risk prediction, diagnostic, and disease monitoring tool for dementia, aiming to detect Alzheimer's disease

Huimei Technology

Series D in 2023
Huimei Technology is a National high-tech enterprise that offers medical artificial intelligence solutions.

CSR Biotech

Series A in 2023
CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.

Epigenic Therapeutics

Series A in 2023
Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Saints & Sages

Series B in 2023
Saints & Sages Medical specializes in the development and production of minimally invasive surgical medical devices. The company offers a range of energy devices that are utilized across various medical fields, including hepatobiliary, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. With a commitment to addressing clinical needs, Saints & Sages focuses on innovation in surgical technology. They leverage a dedicated research and development team and extensive clinical experience to create devices that enhance the precision and efficiency of surgical procedures, ultimately aiming to improve patient outcomes globally.

Yanshengchao

Angel Round in 2023
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

Atantares

Seed Round in 2023
Atantares is a biotechnology company that leverages semiconductor technology to advance biomedicine through innovative microfluidics solutions. By utilizing the miniaturization and integration capabilities of silicon chips, the company develops precision medicines and smart diagnostic devices aimed at transforming disease management in hematology, cardiology, neurology, and oncology. Atantares offers a proprietary coagulation device designed to monitor specific drugs and blood products, employing coagulation assays that assess platelet function, clotting times, and viscoelasticity. Furthermore, the company focuses on creating a chimeric antigen receptor for the treatment of hematological tumors and various diseases, utilizing an ultrasensitive immunoassay platform to provide crucial cytokine profile data for the effective management of CAR T-cell therapy and cytokine release syndrome mitigation.

Cornerstone Robotics

Series B in 2023
Cornerstone Robotics is a company dedicated to enhancing the accessibility of advanced medical services in China through the development of innovative medical robotic devices. Its primary focus lies in creating a safe and efficient surgical robotics platform that empowers physicians to perform surgeries with greater accuracy and efficiency. By investing in research and development, Cornerstone Robotics aims to advance the field of surgical robotics, thereby improving patient outcomes and transforming surgical practices.

BayOmics

Seed Round in 2023
BayOmics is a high-tech enterprise specializing in the commercial development and application of proteomics research. The company utilizes integrated automated proteomics technology to perform functional proteome analysis and facilitate the discovery of new drug targets. By focusing on targeted drug research and development using micro-clinical samples, BayOmics aims to provide crucial technical support to the medical industry. This support is particularly geared towards the development of treatments for critical illnesses, including cancer and other significant diseases.

Thorough Future

Series A in 2023
Thorough Future specializes in incorporating advanced technology into medical care, focusing on improving diagnostic services in clinical medicine. The company develops artificial intelligence solutions to enhance pathology image diagnosis, utilizing big data and AI to deliver intelligent diagnostic and predictive services. By doing so, Thorough Future aims to increase the efficiency of diagnoses and offer personalized treatment recommendations, particularly for cancer patients, thus contributing to improved patient outcomes in healthcare.

LTZ Therapeutics

Seed Round in 2023
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Ailomics Therapeutics

Angel Round in 2023
Ailomics Therapeutics, established in 2022 with headquarters in Shanghai, China, specializes in developing novel drugs for treating immune diseases and tumors. The company employs a computational biology platform to analyze multi-omics patient data, aiming to uncover new drug targets and mechanisms driving disease progression.

CuroVax

Series B in 2023
CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. The company offers a range of vaccines, including a freeze-dried rabies vaccine for human use and an influenza virus split vaccine. CuroVax employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and mRNA vaccine development. It provides biotechnology and microbiology services, focusing on improving health and medical industry standards.

DK Medtech

Venture Round in 2023
DK Medtech is a medical technology company based in Suzhou, China, specializing in the development and production of balloon catheter medical devices. Founded in 2015, the company has positioned itself as a leader in the medical device industry, focusing on innovative solutions to address complex healthcare challenges. Through its commitment to excellence, DK Medtech aims to improve patient outcomes and enhance the quality of healthcare.

Abdera Therapeutics

Series B in 2023
Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company employs a precision oncology platform that utilizes purpose-built vectors to deliver high-energy radio-isotopes directly to tumors and metastatic lesions. This innovative approach to targeted radiotherapy aims to improve treatment efficacy for patients with challenging cancer diagnoses. Abdera's work in this emerging field aligns with a significant market potential, as targeted alpha therapies are expected to play a major role in the future of nuclear medicine.

Brise Pharma

Series A in 2023
Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

1 Yong Cloud

Series B in 2023
1 Yong Cloud is a Beijing-based company founded in 2017 that specializes in developing and operating a tumor diagnosis and treatment standardization platform. The platform is designed to assist healthcare professionals in formulating personalized diagnosis and treatment plans for patients with tumor diseases. By collecting and translating medical data, 1 Yong Cloud aims to enhance the quality and standardization of medical practices while rationalizing treatment expenses. Through its comprehensive data and system services, the company supports physicians in making informed decisions to improve patient outcomes.

Caidya

Series D in 2023
Caidya is a clinical research organization based in North Carolina, founded in 2021. The company specializes in providing personalized solutions across various therapeutic areas and focuses on enhancing clinical development capabilities. Caidya operates a proprietary technology platform that integrates data from multiple systems to deliver near real-time insights into clinical trials. Additionally, it offers advisory services related to clinical development plans, regulatory strategies, approval processes, and clinical trial support. By facilitating the globalization of innovative drugs and improving clinical trial efficiency, Caidya aims to increase the likelihood of success for biopharmaceutical and medical companies.

Ricoton

Series A in 2023
Ricoton is a medical device company based in Hunan, China, specializing in the development and production of devices for cerebrovascular diseases. Founded in 2011, the company offers a range of products designed for interventional medicine, including microcatheters, guidewires, and various vascular access devices. Notably, Ricoton's equipment features a comprehensive set that includes a micro guide wire, micro catheter, support catheter, thrombectomy stent, balloon guide catheter, and intracranial balloon dilatation catheter. This innovative lineup provides a one-stop thrombectomy solution aimed at enhancing the treatment and prevention of cerebrovascular conditions.

Allorion Therapeutics

Series B in 2023
Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

Vongi

Series B in 2023
Vongi offers medical solution design, product design and RandD, pilot test transformation, clinical research, registration services, and commercial operations for companies that need digital therapy, real-world research, and digital therapy CDMO and process services. For inquiries, their email address, telephone number, and physical address are available on their website.

SinoUnited Health

Series C in 2023
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopedics, and neurology services. Established in 2004, the center offers a wide range of treatments, including services for foot and ankle issues, acupuncture, chronic pain, movement disorders, migraines, tremors, electromyography, balance training, home exercise programs, manual therapy, post-stroke care, post-herpetic neuralgia, osteoarthritis, and carpal tunnel syndrome. Known for its commitment to high-quality patient care, SinoUnited Health integrates thoughtful design with international standards to enhance the patient experience. The center has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, ensuring high levels of customer satisfaction among both local residents and visitors.

Tingsheng Technology

Series B in 2023
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.

Singular Medical

Series B in 2023
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

Biotree Technology

Series A in 2023
Biotree Technology is a high-tech enterprise that specializes in the application, consulting, and development of advanced research technologies within the life sciences sector. Focusing on mass spectrometry and metabolomics, the company provides comprehensive solutions for early detection and analysis in China. With a strong core team experienced in metabolomics, Biotree Technology offers services in scientific research, health testing, and industrial testing. The company is recognized for its innovation in metabolomics products and technology, holding several patents in the field. It has established itself as a leader in metabolomics detection and analysis, maintaining steady growth and profitability over the years. Through its biotechnological testing and consulting services, Biotree Technology assists clients in testing product quality and conducting various biotechnological research projects.

Bio-Link

Series A in 2022
Bio-Link is a drug development company founded in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, including the development and manufacturing of key process equipment and consumables. Bio-Link's offerings include technologies for vaccines, antibody drugs, cell therapy, gene therapy, and various biologics. The company focuses on upstream cell culture, disposable dispensing reservoirs, and downstream processes such as chromatography and ultrafiltration. By delivering innovative products and services, Bio-Link aims to enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, the company explores wearable technology solutions for elderly care, further diversifying its portfolio.

Newsoara

Venture Round in 2022
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Fitlens

Series B in 2022
Fitlens is a company that provides ophthalmic medical treatment. They specialize in the design and manufacture of high-end, complicated optical contact lenses as well as the design and manufacture of high-end intraocular lens optical molds.

Reunion Biotech

Series A in 2022
Reunion Biotech focuses on the research and development and industrial transformation of medical hydrogels. The company is committed to becoming an international leading hydrogel technology platform. The current pipeline includes systemic solutions for tumor radiotherapy protection, wound repair, tumor embolization, and drug delivery.

Entact Bio

Series A in 2022
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

BayOmics

Series A in 2022
BayOmics is a high-tech enterprise specializing in the commercial development and application of proteomics research. The company utilizes integrated automated proteomics technology to perform functional proteome analysis and facilitate the discovery of new drug targets. By focusing on targeted drug research and development using micro-clinical samples, BayOmics aims to provide crucial technical support to the medical industry. This support is particularly geared towards the development of treatments for critical illnesses, including cancer and other significant diseases.

Sunny Dental

Series A in 2022
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a comprehensive range of orthodontic services. The company provides diagnosis and treatment for dental implants, children’s dentistry, dental restorations, periodontal disease, dental pulp issues, and oral and maxillofacial surgery. Sunny Dental is dedicated to offering professional care and advanced solutions in various aspects of dental health, ensuring a focus on both preventative and restorative treatments.

Core Medical

Series B in 2022
Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.

Thorough Future

Series A in 2022
Thorough Future specializes in incorporating advanced technology into medical care, focusing on improving diagnostic services in clinical medicine. The company develops artificial intelligence solutions to enhance pathology image diagnosis, utilizing big data and AI to deliver intelligent diagnostic and predictive services. By doing so, Thorough Future aims to increase the efficiency of diagnoses and offer personalized treatment recommendations, particularly for cancer patients, thus contributing to improved patient outcomes in healthcare.

Soda Health

Series A in 2022
Soda Health, established in 2021 with its headquarters in Chicago, Illinois, is a healthcare technology company focused on reducing health disparities by addressing social determinants of health. The company operates a platform designed to help individuals identify, access, and afford necessary resources for leading healthier lives. This platform facilitates personalized benefit administration and reimbursement, bridging the gap between medical claims and retail payments more cost-effectively than traditional methods.

Dezhen Technology

Series A in 2022
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.

CSR Biotech

Seed Round in 2022
CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.

XellSmart

Series A in 2022
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Fushoukang

Series C in 2022
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Insilico Medicine

Series D in 2022
Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Ailomics Therapeutics

Seed Round in 2022
Ailomics Therapeutics, established in 2022 with headquarters in Shanghai, China, specializes in developing novel drugs for treating immune diseases and tumors. The company employs a computational biology platform to analyze multi-omics patient data, aiming to uncover new drug targets and mechanisms driving disease progression.

Norm Medtech

Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.

GYENNO Technologies

Series B in 2022
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.

Atantares

Angel Round in 2022
Atantares is a biotechnology company that leverages semiconductor technology to advance biomedicine through innovative microfluidics solutions. By utilizing the miniaturization and integration capabilities of silicon chips, the company develops precision medicines and smart diagnostic devices aimed at transforming disease management in hematology, cardiology, neurology, and oncology. Atantares offers a proprietary coagulation device designed to monitor specific drugs and blood products, employing coagulation assays that assess platelet function, clotting times, and viscoelasticity. Furthermore, the company focuses on creating a chimeric antigen receptor for the treatment of hematological tumors and various diseases, utilizing an ultrasensitive immunoassay platform to provide crucial cytokine profile data for the effective management of CAR T-cell therapy and cytokine release syndrome mitigation.

Gaugene

Series B in 2022
Gaugene is a high-tech enterprise that specializes in the development and supply of hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. The company offers advanced instruments and reagents that play a critical role in hematology diagnosis, as well as broader clinical diagnostics and life science research. Gaugene is notable for being the only manufacturer in China that incorporates high-power flow lasers and high-sensitivity multi-color fluorescence detection systems in its products. This technological edge enables the company to provide innovative solutions for clinical diagnosis, flow cytometry technology, single cell research, protein screening, and the discovery of new clinical indicators. Gaugene is co-sponsored by experienced professionals from renowned domestic IVD companies, ensuring a strong foundation in industry-leading technologies.

Biotree Technology

Series A in 2022
Biotree Technology is a high-tech enterprise that specializes in the application, consulting, and development of advanced research technologies within the life sciences sector. Focusing on mass spectrometry and metabolomics, the company provides comprehensive solutions for early detection and analysis in China. With a strong core team experienced in metabolomics, Biotree Technology offers services in scientific research, health testing, and industrial testing. The company is recognized for its innovation in metabolomics products and technology, holding several patents in the field. It has established itself as a leader in metabolomics detection and analysis, maintaining steady growth and profitability over the years. Through its biotechnological testing and consulting services, Biotree Technology assists clients in testing product quality and conducting various biotechnological research projects.

Ark Biosciences

Series D in 2022
Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

RiboX Therapeutics

Series B in 2022
RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.

Boulder Care

Series B in 2022
Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.

Purevision

Seed Round in 2022
Purevision is a technological start-up company that focuses on innovative ophthalmic medical devices.

Insilico Medicine

Series D in 2022
Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Yanshengchao

Seed Round in 2022
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

Ashermed

Series B in 2022
Ashermed is a provider of contract research organization (CRO) services specifically designed for medical companies. The company emphasizes the integration of advanced technologies, such as Internet technology, big data, and artificial intelligence, to enhance the drug development process. By leveraging these technologies, Ashermed aims to shorten the clinical data development cycle and improve the quality of research outcomes, ultimately reducing research and development costs for its clients. Their offerings include CRO services, site management organization (SMO) support, patient recruitment, and digital platform assistance, all tailored to facilitate the needs of the medical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.